Covid-19: Global vaccine program COVAX low on funds, seeks $5.2 billion

The UN-backed programme known as COVAX has delivered just over 1 billion doses since shipments started nearly a year ago

Covaxin has started trials on children; it would be for children who are two years or older
Representational image
AP Geneva
1 min read Last Updated : Jan 20 2022 | 1:37 AM IST

The global initiative to share coronavirus vaccines equally between rich and poor countries asked Wednesday for USD 5.2 billion in funds to be able to keep buying doses in coming months.

The UN-backed programme known as COVAX has delivered just over 1 billion doses since shipments started nearly a year ago.

The initial goal was to deliver 2 billion doses by the end of 2021, but COVAX's lack of cash when vaccine deals were being made gave it a late start, and most of the world's vaccine doses have gone to wealthy nations who locked in contracts.

As things stand now, less than 10 per cent of the people in low-income countries have received at least one dose, while more than 60 per cent of world's overall population has been vaccinated some with three or four doses.

Seth Berkley, the CEO of GAVI, the global health organization that co-founded the COVAX initiative, said it was key to supplying poor countries with vaccine shots now and in the future but we right now are basically out of money.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Jan 20 2022 | 1:37 AM IST

Next Story